Download or read book Examining the 340b Drug Pricing Program written by United States. Congress and published by Createspace Independent Publishing Platform. This book was released on 2017-09-17 with total page 112 pages. Available in PDF, EPUB and Kindle. Book excerpt: Examining the 340B drug pricing program : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fourteenth Congress, first session, March 24, 2015.
Download or read book Examining the 340B Drug Pricing Program written by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and published by . This book was released on 2015 with total page 112 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Examining Oversight Reports on the 340B Drug Pricing Program written by United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions and published by . This book was released on 2020 with total page 46 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Examining the 340B Drug Pricing Program written by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and published by . This book was released on 2015 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Examining the 340B Drug Pricing Program Hearing Serial No 114 25 March 24 2015 114 1 written by and published by . This book was released on 2015* with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Examining HRSA s Oversight of the 340B Drug Pricing Program Serial No 115 46 July 18 2017 115 1 written by and published by . This book was released on 2018 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Examining How Covered Entities Utilize the 340B Drug Pricing Program written by and published by . This book was released on 2017 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Perspectives on the 340B Drug Pricing Program written by United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions and published by . This book was released on 2020 with total page 70 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Examining HRSA s Oversight of the 340B Drug Pricing Program written by and published by . This book was released on 2018 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Examining How Covered Entities Utilize The 340B Drug Pricing Program Hearing Serial No 115 63 October 11 2017 115 1 written by and published by . This book was released on 2019 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Effective Administration of the 340B Pricing Program written by and published by . This book was released on 2020 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Effective Administration of the 340B Drug Pricing Program written by United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions and published by . This book was released on 2020 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Examining how Covered Entities Utilize the 340B Drug Pricing Program written by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations and published by . This book was released on 2019 with total page 184 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Examining HRSA s Oversight of the 340B Drug Pricing Program written by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations and published by . This book was released on 2018 with total page 104 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Effects of the 340B Drug Pricing Program on Hospitals Prescribing Behavior Patient Mix and Quality of Care written by Yilu Dong and published by . This book was released on 2020 with total page 143 pages. Available in PDF, EPUB and Kindle. Book excerpt: In 1992, Congress created the 340B Drug Pricing Program that requires drug manufacturers to provide outpatient drugs to participating hospitals with substantial discounts. Although the intent of the program is to allow covered entities to increase access to care for more vulnerable patients, hospitals are not required by law to pass on the discounts. Therefore, a concern is that hospitals might over-prescribe. This dissertation includes three chapters to study the effects of the 340B program on hospitals’ behavior changes: Chapter 1 uses state aggregate hospital service spending data from the Centers for Medicare and Medicaid Services (CMS) to study the nation-wide impact of state 340B hospital participation on state hospital service spending. Controlling for state fixed effects, time fixed effects and state specific time trends, I find, on average, a 1 percentage point increase in state 340B hospital share leads to a 12.8% increase in state hospital service spending per capita. With only hospital spending data, analysis in this chapter cannot distinguish between a scenario where hospitals increase their spending to improve quality of care, consistent with the intent of the 340B program, and a scenario where hospitals are simply increasing spending without improving quality to maximize profit. Chapter 2 complements the analysis in Chapter 1 by exploring the causal impact of the 340B program on hospitals' medication cost, patient mix and quality of care. Working with 15 million ambulatory visits to Florida hospitals from 2005 to 2015, I use a series of difference-in-difference (DID) and synthetic control methods (SCM) based on the 2010 340B eligibility expansion, I find an average increase of $111.35 in medication cost per visit due to the 2010 expansion. Quantile regressions reveal that hospitals with the highest proportion of charity care and uninsured patients keep medication cost low and on the most expensive visits, they significantly reduce medication cost for patients. The remaining newly eligible hospitals significantly raise medication cost after the expansion. The increase becomes larger the more expensive the treatment is. Finally, I find some indications that newly eligible hospitals increased Medicaid patient mix and improved quality of care, but the evidence is not strong enough to be conclusive. Chapter 3 further extends the analysis by examining the impact of market power on 340B hospitals' behavior changes. Using the CMS nation-wide state aggregate data, I find the positive relationship between the state's 340B hospital share and state aggregate hospital service spending is stronger when hospitals' market share is higher. Working with the Florida data, using a series difference-in-difference-indifference (DDD) regressions, complemented by DID and SCM estimations, I find the 340B hospitals with low market shares seem to fulfill the mission of the program by keeping medication cost low, treating more low-income patients covered by Medicaid and Medicaid managed care and provide more charity to the communities. Compared to them, hospitals with high market shares significantly raise additional medication cost, treat fewer low-income patients but substantially more commercially insured patients. There are some signs of post-expansion quality improvement among all the newly eligible hospitals, measured by the post-operative adverse reaction rates, but heterogeneity exists in hospitals' length of stay and nonroutine discharge rates. Hospitals with high market shares seem to treat more patients in their own outpatient facilities with a shorter length of stay. While the ones with low market shares experience increased length of stay, possibly due to worse health conditions among the additional Medicaid and Medicaid managed care patients they treat. As a summary, this dissertation finds the average 340B hospital raise their medication cost upon participation in the program, but heterogeneity exists that some of them seem to fulfill the mission of the program. There are signs of quality improvement in the data, but future research could adopt more quality measures to study the cost-effectiveness on the price increase, as well as the welfare influence on the cost reduction.
Download or read book Drug Pricing written by Debra A. Draper and published by . This book was released on 2011-09-23 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: The Health Resources and Services Admin. (HRSA) oversees the 340B Drug Pricing Program, through which participating drug manufacturers give certain entities within the health care safety net -- known as covered entities (CE) -- access to discounted prices on outpatient drugs. CE include specified fed. grantees and hospitals. The number of CE sites has nearly doubled in the past 10 years to over 16,500. This study examines: (1) the extent to which CE generate 340B revenue, factors that affect revenue generation, and how they use the program; (2) how manufacturers' dist. of drugs at 340B prices affects CE or non-340B providers' access to drugs; and (3) HRSA's oversight of the 340B program. Charts and tables. A print on demand report.
Download or read book 340B Drug Pricing Program written by Andrea Radford and published by . This book was released on 2007 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
